Scienmag
MAY 12, 2022
of the University of Alabama at Birmingham have made what they call “a major step” in understanding how Mycobacterium tuberculosis acquires iron from its human host — a process essential for the pathogenesis of this bacterium. . – Lei Zhang, Ph.D., and Michael Niederweis, Ph.D.,
Scienmag
FEBRUARY 5, 2021
Treatment causes deadly bacterium to leak and die Credit: Hailing Jin/UCR New research affirms a unique peptide found in an Australian plant can destroy the No. 1 killer of citrus trees worldwide and help prevent infection. Huanglongbing, HLB, or citrus greening has multiple names, but one ultimate result: bitter and worthless citrus fruits.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
NOVEMBER 19, 2020
Structural insights about a deadly bacterium’s toolbox point to ways to block it Credit: Maria Schumacher Lab, Duke Biochemistry DURHAM, N.C. – The bacterium that causes the tick-borne disease tularemia is a lean, mean infecting machine.
XTalks
NOVEMBER 6, 2020
The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. BacTRL Gene Therapy Platform. Related: Red Meat Allergy Test Gets FDA Clearance. “We
The Pharma Data
JUNE 14, 2023
Pseudomonas aeruginosa, a common environmental bacterium, can colonize different body parts, such as the lungs, leading to persistent, chronic infections that can last a lifetime – a common occurrence in people with cystic fibrosis. “And at this point, the function of the gene was unknown.” and Nelson D.
The Pharma Data
JULY 11, 2021
On the other hand, they can inhibit specific enzymes that regulate the accessibility to the genetic material and thus the gene expression in the T cells. On the one hand, they can boost the metabolism of T cells by inducing central regulators of energy metabolism. In doing so, they induce epigenetic changes.
XTalks
AUGUST 2, 2023
Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A. 2022 was the first year on market for cell-based gene therapies Abecma (Idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel) , which generated $388 million and $182 million, respectively. Both are anti-CD20 agents.
Expert insights. Personalized for you.
84 
Let's personalize your content